Equities Analysts Offer Predictions for NBIX FY2026 Earnings

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - HC Wainwright dropped their FY2026 earnings per share estimates for Neurocrine Biosciences in a note issued to investors on Tuesday, April 22nd. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of $4.33 for the year, down from their prior estimate of $4.43. HC Wainwright has a "Buy" rating and a $168.00 price objective on the stock. The consensus estimate for Neurocrine Biosciences' current full-year earnings is $4.28 per share. HC Wainwright also issued estimates for Neurocrine Biosciences' FY2027 earnings at $7.09 EPS and FY2029 earnings at $14.31 EPS.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%.

Several other analysts have also recently weighed in on NBIX. William Blair reissued an "outperform" rating on shares of Neurocrine Biosciences in a report on Friday, February 7th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Neurocrine Biosciences in a research note on Tuesday, February 11th. They issued a "hold" rating and a $138.00 price objective for the company. Bank of America dropped their price objective on shares of Neurocrine Biosciences from $184.00 to $179.00 and set a "buy" rating for the company in a report on Friday, February 7th. Guggenheim decreased their price target on Neurocrine Biosciences from $165.00 to $163.00 and set a "buy" rating for the company in a research note on Monday, February 10th. Finally, Canaccord Genuity Group cut their price target on shares of Neurocrine Biosciences from $163.00 to $158.00 and set a "buy" rating on the stock in a research report on Monday. Three investment analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $160.90.

Neurocrine Biosciences Price Performance

Neurocrine Biosciences stock traded down $1.67 during mid-day trading on Wednesday, hitting $105.07. 408,734 shares of the company's stock traded hands, compared to its average volume of 1,065,919. The firm has a 50 day simple moving average of $107.16 and a two-hundred day simple moving average of $122.22. The stock has a market cap of $10.39 billion, a price-to-earnings ratio of 31.88, a P/E/G ratio of 0.77 and a beta of 0.33. Neurocrine Biosciences has a fifty-two week low of $84.23 and a fifty-two week high of $157.98.

Institutional Investors Weigh In On Neurocrine Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in Neurocrine Biosciences by 1.2% in the 4th quarter. Vanguard Group Inc. now owns 10,119,641 shares of the company's stock worth $1,381,331,000 after buying an additional 122,681 shares in the last quarter. Dodge & Cox grew its stake in Neurocrine Biosciences by 134.2% during the fourth quarter. Dodge & Cox now owns 3,016,425 shares of the company's stock valued at $411,742,000 after acquiring an additional 1,728,605 shares in the last quarter. AQR Capital Management LLC increased its holdings in Neurocrine Biosciences by 2.9% in the 4th quarter. AQR Capital Management LLC now owns 1,896,891 shares of the company's stock valued at $258,926,000 after acquiring an additional 53,610 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Neurocrine Biosciences by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 1,875,062 shares of the company's stock valued at $255,523,000 after purchasing an additional 15,830 shares during the last quarter. Finally, Wellington Management Group LLP grew its position in shares of Neurocrine Biosciences by 102.9% during the fourth quarter. Wellington Management Group LLP now owns 1,457,425 shares of the company's stock valued at $198,939,000 after purchasing an additional 739,199 shares in the last quarter. 92.59% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, insider Julie Cooke sold 1,740 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $152.89, for a total transaction of $266,028.60. Following the sale, the insider now directly owns 18,202 shares of the company's stock, valued at $2,782,903.78. This trade represents a 8.73 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Kevin Charles Gorman sold 5,844 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $116.69, for a total transaction of $681,936.36. Following the transaction, the director now directly owns 521,618 shares of the company's stock, valued at $60,867,604.42. The trade was a 1.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 21,801 shares of company stock worth $2,834,677. 4.30% of the stock is owned by corporate insiders.

Neurocrine Biosciences declared that its board has authorized a stock repurchase plan on Friday, February 21st that permits the company to buyback $500.00 million in shares. This buyback authorization permits the company to buy up to 4.2% of its stock through open market purchases. Stock buyback plans are generally a sign that the company's board of directors believes its stock is undervalued.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.